D007189Chemicals & DrugsD02.455.426.559.847.486.487D04.615.486.48721310.968565Indansplugins:TwitterTwitterFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAnesthesia and Critical CareMedicine-Gastroenterology1.85440.011726821research area of0.9939460.048429622subject area for33438008Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens GJournal of Crohn's & colitisLong-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.J Crohns Colitis2021-07-05T00:00:002021Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.34587385Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study GroupThe New England journal of medicineOzanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291.N Engl J Med2021-09-30T00:00:002021Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.35212384Choi DK, Rubin DT, Puangampai A, Cleveland NInflammatory bowel diseasesHypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.Inflamm Bowel Dis2022-08-01T00:00:002022Hypertensive Emergency After Initiating Ozanimod: A Case Report.https://tangcenter.uchicago.edu/Tang Center for Herbal Medicine Researchhttps://rubinlab.uchicago.edu/Rubin Lab Sitehttps://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-diseaseInflammatory Bowel Disease CenterIBDMDMedicineUniversity of ChicagoChong-ZhiWangChong-Zhi Wang41.78927490000000-87.601250000000001193Wang, Chong-ZhiResearch Associate ProfessorNoaClevelandNoa Cleveland41.7886000000000087.598699999999994436Cleveland, NoaAssistant Professor37651686Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, Afzali A, Wolf DC, Chiorean MV, Vermeire S, Jain A, Charles L, Lawlor G, Osterman MT, Wu H, Canavan JB, Petersen A, Colombel JF, Regueiro MJournal of Crohn's & colitisEfficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.J Crohns Colitis2024-02-26T00:00:002024Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.JerroldLeikinJerrold Leikin41.78927490000000-87.601250000000002380Leikin, JerroldClinical ProfessorDavid T.RubinDavid T. Rubin41.78927490000000-87.60125000000000256Rubin, David T.ProfessorStephenHanauerStephen B. Hanauer41.78927490000000-87.60125000000000660Hanauer, StephenEmeritus/Emerita38087126Cohen NA, Choi D, Garcia N, Choi NK, Picker E, Krugliak Cleveland N, Cohen RD, Dalal SR, Pekow J, Rubin DTDigestive diseases and sciencesReal World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.Dig Dis Sci2023-12-12T00:00:002023Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.true1Research Associate ProfessorResearch Associate Professortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1Emeritus/EmeritaEmeritus/Emeritatrue1Assistant ProfessorAssistant Professor1010